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Abstract 
STUDY QUESTION 
Are boys who are born to mothers who use analgesics during pregnancy at increased risk of 
cryptorchidism compared to those born to mothers who do not take analgesia? 
SUMMARY ANSWER 
In this systematic review and meta-analysis of 10 published studies, we observed only weak 
evidence of an association between analgesia use during pregnancy and risk of cryptorchidism in 
the son. 
WHAT IS KNOWN ALREADY 
Concentrations of analgesia relevant to human exposure have been implicated as causing endocrine 
disturbances in the developing foetal testis. However, when viewed collectively there appears to be 
conflicting evidence regarding an association between maternal use of analgesics and development 
of cryptorchidism. 
STUDY DESIGN, SIZE, DURATION 
A systematic review and meta-analysis of studies on analgesia use during pregnancy and risk of 
cryptorchidism was performed. The search terms used were (analges* OR paracetamol OR 
acetaminophen) AND (cryptorchidism OR cryptorchism OR undescended test* OR non-descended 
test* OR non descended test*) for the databases Ovid Medline, Embase, Scopus and Web of 
Science. The search included all published articles up until 23 May 2016 and no limits were set in 
terms of language. 
PARTICIPANTS/MATERIALS, SETTING, METHODS 
Abstracts were screened by one reviewer to remove irrelevant studies, with a 10% random sample 
of these verified by a second reviewer. The full text of all remaining papers was assessed by two 
reviewers. Abstracts included in the final analysis were studies which reported associations between 
the exposure (analgesia) and the outcome (cryptorchidism). Studies were only included if data were 
provided from which summary associations (odds ratios (ORs) or relative risks) and their 95% CIs 
could be calculated, or if summary associations were provided by the authors themselves. For each 
included study, two reviewers independently extracted study meta-data in line with PRISMA 
recommendations. We assessed study quality and potential for bias using the criteria outlined in the 
Newcastle-Ottawa Quality Assessment Scale, but did not determine a quality score. Two reviewers 
independently assessed study quality against these criteria. 
MAIN RESULTS AND THE ROLE OF CHANCE 
After screening 350 manuscripts, 10 were included in our review (5 case-control studies, 5 cohort 
studies). We observed weak evidence of an association between ever use of analgesia and risk of 
cryptorchidism (pooled crude OR: 1.11, 95% CI: 1.00–1.23), with case-control studies revealing a 
marginally stronger association (1.23, 95% CI: 0.85–1.78) than cohort studies (1.09, 95% CI: 0.97–
1.22). We observed weak evidence of a dose-response relationship between increasing weeks of 
analgesia exposure and risk of cryptorchidism, as well as weak evidence of an effect of timing on 
analgesia exposure and risk of cryptorchidism. Assessment of study quality via the Newcastle-
Ottawa criteria revealed little (if any) evidence of substantial bias that may have meaningfully 
affected a given study's results. 
LIMITATIONS, REASONS FOR CAUTION 
While confounding does not appear to be important, misclassification of the exposure is possibly an 
important source of measurement error in this context. The systematic review is open to reporting 
bias. Owing to scant data, no meta-analyses for two key questions (relating to dose-response and 
timing of exposure) could be performed. Medications were grouped based on their common effect 
and this offers little insight into the relation between specific types of analgesia and cryptorchidism. 
Finally, there are limitations in assuming that analgesia use reported by mothers is synonymous 
with actual intrauterine exposure. 
WIDER IMPLICATIONS OF THE FINDINGS 
The ubiquity of analgesia use during pregnancy makes this exposure particularly important from a 
population health perspective. About 9 of the 10 studies were conducted in Europe or USA, limiting 
generalizability of our observations. While the observations from our systematic review and meta-
analysis suggest that analgesia use during pregnancy is not strongly associated with cryptorchidism 
development in the son, they also highlight the need for further detailed assessments of this 
relationship. 
Keywords: cryptorchidism, cryptorchism, analgesia, painkiller, paracetamol, congenital 
abnormality, pregnancy 
Introduction 
Although rare in absolute terms, cryptorchidism—failure of the testes to descend permanently into 
their terminal scrotal position—is one of the most common congenital anomalies to affect boys 
(Ansell et al., 1992). Cryptorchidism is one of the few known risk factors for testicular cancer, 
wherein males who have suffered cryptorchidism are nearly five times more likely to develop 
testicular cancer than those who have not (relative risk: 4.8, 95% CI: 4.0–15.7) (Dieckmann and 
Pichlmeier, 2004). Cryptorchidism is also a risk factor for sub-fertility: men with a history of 
cryptorchidism are twice as likely to be sub-fertile (10.5%) compared to those without 
cryptorchidism (5.4%) (Lee et al., 1996). Risk factors for cryptorchidism remain unclear, but may 
be related to disruptions to normal endocrine function sometime during the two phases of testicular 
descent (8–15 weeks and 25–35 weeks gestation, respectively) (Hutson et al., 2016). 
The use of medicines to relieve pain—collectively referred to as analgesics—is ubiquitous: a recent 
study of nearly 40 000 Norwegian adults observed that 47% took an over-the-counter analgesic at 
least once per week, the most common being paracetamol (also known as acetaminophen) (Dale et 
al., 2015). Use is also common in pregnancy: in a study of 47 000 mothers of boys, Jensen et al. 
(2010) observed that 55% had taken either acetaminophen, ibuprofen or acetylsalicylic acid at some 
point during pregnancy. 
Analgesics have been implicated as endocrine disruptors, and it has been shown that concentrations 
relevant to human exposure can cause endocrine disturbances in the foetal testis (Mazaud-Guittot et 
al., 2013). Several studies have observed a positive association between maternal use of analgesics 
and subsequent development of cryptorchidism in their sons (Berkowitz and Lapinski, 1996; Jensen 
et al., 2010; Kristensen et al., 2011; Snijder et al., 2012). For example, Snijder et al. (2012) 
observed that women who used mild analgesics during their second trimester had more than twice 
the odds of giving birth to sons who had cryptorchidism (adjusted odds ratio (OR): 2.12, 95% CI: 
1.17–3.83), and that up to 24% of all cryptorchidism cases in their cohort could be attributed to 
maternal use of mild analgesics during pregnancy. 
However, there is conflicting evidence regarding this relationship, with several authors finding no 
(Mori et al., 1992; Wagner-Mahler et al., 2011) or weak/limited (Davies et al., 1986; Rebordosa et 
al., 2008; Philippat et al., 2011) evidence of an association. Thus, the following questions remain 
unanswered: are boys who are born to mothers who use analgesia during pregnancy at increased 
risk of cryptorchidism compared to those born to mothers who do not? If an association exists, does 
the risk of cryptorchidism increase with increasing levels of maternal analgesia use? Finally, does 
the timing of maternal analgesia use (e.g. by trimester) affect the risk of cryptorchidism? 
In order to address these questions, we conducted a systematic review and meta-analysis of studies 
of maternal analgesia use and development of cryptorchidism in the son. 
Materials and Methods 
Search strategy 
This study was performed in accordance with PRISMA guidelines (Moher et al., 2009) and 
registered with PROSPERO: CRD42016041414, describing in advance the aims and methods of 
our investigation (Gurney et al., 2016). 
Eligibility	criteria		
The PICOS (Patient/Participant, Intervention, Comparator, Outcome, Study design) criteria used 
are outlined (Supplementary Table S1). Abstracts in the final analysis included studies which 
reported associations between the exposure (analgesia) and the outcome (cryptorchidism), with no 
limit on study design. Studies were only included if data were provided from which summary 
associations (ORs or relative risks) and their 95% CIs could be calculated, or if these summary 
associations were provided by the authors themselves. 
Information	sources		
A systematic review was conducted on 23 May 2016 for all articles published up until that time. No 
limits were set in terms of language used during the initial abstract search. Our search was 
conducted using Ovid Medline, Embase, Scopus and Web of Science databases. The reference list 
of studies considered eligible for inclusion were scanned for additional relevant studies. 
International experts in the field (K.M., L.R.) scanned the list of those studies which met our 
inclusion criteria to identify any studies missed by our search. 
Search	terms		
Using a Boolean approach, we searched the electronic databases for each possible combination of 
the following keywords (* indicates ‘explosion’ term): (analges* OR paracetamol OR 
acetaminophen) AND (cryptorchidism OR cryptorchism OR undescended test* OR non-descended 
test* OR non descended test*) (Supplementary Table SII). References were collected and logged in 
EndNote vX7.1 (Thomson Reuters, NY, USA). 
Study selection and data extraction 
Screening	of	abstracts		
Figure Figure11 shows the flow chart for study identification and inclusion. Duplicate papers were 
removed prior to abstract screening. Abstracts were screened by J.G. to remove irrelevant studies, 
with a 10% random sample of these verified by V.S. The full text of all remaining papers was 
assessed by J.G. and V.S. to identify those meeting our inclusion criteria. Any disagreements about 
inclusion were resolved by referral to D.S. All papers considered relevant during abstract screening 
but ineligible for final inclusion are listed in Supplementary Table SIII.  
Data	extraction		
For each included study, J.G. and V.S. independently extracted study meta-data in line with 
PRISMA recommendations. Data items for which there was any disagreement between the two 
reviewers were referred to D.S. 
Assessment	of	risk	of	bias	(individual	and	across	studies)		
In the absence of a gold standard, it has been recommended that any tools used to measure study 
quality should be as specific as possible to the given topic, and involve a simple checklist as 
opposed to a scale or score (Sanderson et al., 2007). Given these factors, we assessed study quality 
and potential for bias using the criteria outlined in the Newcastle-Ottawa Quality Assessment Scale 
(Wells et al., 2004; Alam et al., 2010), but did not determine a quality score (Burkey et al., 2014). 
J.G. and V.S. independently assessed study quality against these criteria, with disagreements 
resolved by referral to D.S. 
Statistical analysis 
In those instances where it was feasible to conduct meta-analyses, we calculated crude ORs and 
their 95% CIs. This was for two reasons: first, the included studies varied in their reporting of risk 
estimates, with some reporting ORs and one study reporting hazard ratios (HRs). Second, there was 
heterogeneity among studies in terms of adjustment for confounding, with some studies not 
adjusting for confounding whatsoever. 
Since not all studies provided crude ORs, these were calculated from tabulated data provided in the 
manuscripts. Using a random-effects model, we applied inverse-variance weighted methods for 
combining results across included studies to arrive at a final summary OR (and 95% CIs). We tested 
for evidence of heterogeneity among studies using both the χ2 test (with a lower P-value indicating 
high inter-study heterogeneity) (Kirkwood and Sterne, 2003) and I2 index (0% indicating no inter-
study heterogeneity) (Alam et al., 2010). We also generated and visually inspected funnel plots for 
evidence of publication bias. 
Meta-analysis was completed in Stata v11.2 (StataCorp, TX, USA) using the metan and metafunnel 
functions (Sterne et al., 2006). 
Results 
We identified 10 manuscripts that reported associations between analgesia use during pregnancy 
and risk of cryptorchidism in the son (Fig. (Fig.1),1), of which 5 were case-control studies (Davies 
et al., 1986; Mori et al., 1992; Berkowitz and Lapinski, 1996; Banhidy et al., 2007; Wagner-Mahler 
et al., 2011) and 5 were cohort studies (Rebordosa et al., 2008; Jensen et al., 2010; Kristensen et 
al., 2011; Philippat et al., 2011; Snijder et al., 2012). 
Studies were largely conducted among European populations, with eight studies conducted in 
Europe, one in the USA and one in Japan (Table (TableI).I). In terms of outcome measurement, the 
vast majority (8 of 10) used clinical diagnosis either at birth or shortly afterward, with only two of 
the studies (Mori et al., 1992; Jensen et al., 2010) using orchidopexy to define the occurrence of 
cryptorchidism. Due to disease rarity many studies had a small sample, with the number of cases 
ranging from n = 35 (Kristensen et al., 2011) to n = 2051 (Banhidy et al., 2007).  
Assessment of study quality revealed little (if any) evidence of substantial bias that may have 
meaningfully affected a given study's results (Supplementary Tables SIV and SV). There was some 
relatively minor divergence between cases and controls in terms of response rate, with the 
differences in non-response proportions between cases and controls ranging from 13% to 19%. The 
use of self-report to measure exposure status is discussed later. 
We observed a high degree of heterogeneity among studies in terms of adjustment for confounding.  
Ever use of analgesia 
A total of 10 (5 case-control and 5 cohort) studies were included in our assessment of the 
association between ever use of any analgesia during pregnancy and development of cryptorchidism 
(Table III). The adjusted measures of association presented by these studies ranged from 1.00 (Mori 
et al., 1992) to 1.93 (Berkowitz and Lapinski, 1996) for case-control studies, and 0.74 to 1.43 
(Kristensen et al., 2011) for cohort studies. Where both crude and adjusted estimates were 
presented, adjustment for confounding had little if any impact.  
Meta-analysis of crude ORs (Fig. (Fig.2)2) revealed little evidence of a strong association between 
ever use of analgesia during pregnancy and risk of cryptorchidism in the son (pooled crude OR: 
1.11, 95% CI: 1.00–1.23; case-control studies: 1.23, 95% CI: 0.85–1.78; cohort studies 1.09, 95% 
CI: 0.97–1.22). While there was low heterogeneity among cohort studies (I2 0%, P = 0.820), there 
was some evidence of moderate heterogeneity among case-control studies (I2 44%, P = 0.128). 
When studies were combined, there was low overall heterogeneity across studies (I2 0%, P = 0.46). 
A funnel plot revealed no strong evidence of publication bias (Supplementary Fig. S1).  
Dose-response 
Two studies, both of which were cohort studies, presented data on a possible dose-response 
association between use of analgesia during pregnancy and development of cryptorchidism (Jensen 
et al., 2010; Kristensen et al., 2011). 
When investigating cryptorchidism in Danish and Finnish cohorts, Kristensen et al. (2011) 
observed a dose-response association between analgesia use during pregnancy in their Danish 
cohort (adjusted ORs: 1–2 weeks use [compared to 0 weeks] 1.5, 95% CI: 0.63–3.55; >2 weeks use 
2.47, 95% CI: 1.02–5.96) but not in their Finnish cohort (1–2 weeks use 1.21, 95% CI: 0.50–2.90; 
>2 weeks use 0.56, 95% CI: 0.13–2.45). Jensen et al. (2010) also observed a weak dose-response 
association, although this association marginally attenuated at the most extreme exposure level 
(adjusted HRs: 1 week [compared to 0 weeks] 1.09, 95% CI: 0.89–1.34; 2–4 weeks 1.01, 95% CI: 
0.81–1.28; 5–8 weeks 1.32, 95% CI: 0.97–1.78; 9–12 weeks 1.35, 95% CI: 0.88–2.05; >12 weeks 
1.23, 95% CI: 0.90–1.66). 
Timing of analgesia exposure 
Four (cohort) studies assessed timing of analgesia use and risk of cryptorchidism (Jensen et al., 
2010; Kristensen et al., 2011; Philippat et al., 2011; Snijder et al., 2012). Where both crude and 
adjusted estimates were presented adjustment for confounding had only marginal impact. 
When investigating risk of cryptorchidism in both a Danish and a Finnish cohort, Kristensen et al. 
(2011) observed a stronger association between use of analgesia during the second trimester 
(adjusted OR: Danish cohort 2.30, 95% CI: 1.12–4.73; Finnish cohort 1.21, 95% CI: 0.53–2.76) 
compared to the first (Danish cohort 1.48, 95% CI: 0.66–3.34; Finnish cohort 0.77, 95% CI: 0.26–
2.27). Similarly, Jensen et al. (2010) observed a stronger association for analgesia use during the 
second trimester (adjusted HR: 1.17, 95% CI: 0.89–1.54) compared to the first (0.94, 95% CI: 0.75–
1.17), but also observed a small attenuation of this association for use during the third trimester 
(1.08, 95% CI: 0.87–1.33). Snijder et al. (2012) observed a stronger association for analgesia use 
during mid-pregnancy (crude OR: 2.04, 95% CI: 1.15–3.62) compared to early (0.97, 95% CI: 
0.38–2.48) and late pregnancy (1.56, 95% CI: 0.80–3.03). 
Discussion 
Our meta-analysis suggests that ever use (compared to never-use) of analgesia during pregnancy is 
weakly associated with the development of cryptorchidism (pooled crude OR: 1.11, 95% CI: 1.00–
1.23). However, this lack of a clear association may reflect poor exposure specificity, since ever use 
pools those who may have been exposed only once with those who may have been routinely 
exposed. This would result in misclassification of the exposure, which is likely to bias the observed 
associations towards the null. 
On the other hand, it is also possible that in retrospective studies mothers with affected sons might 
overestimate their exposure relative to those with unaffected sons—which could explain the 
marginally stronger association observed for the case-control studies. However, the difference 
between these two point estimates is not large (1.23 vs 1.09), suggesting that recall bias is not of 
substantial importance in this context. 
We observed remarkable heterogeneity in the prevalence of ever use between study populations—
ranging from near 0% prevalence up to 94% prevalence (Table III). While there was a tendency for 
this prevalence to be higher in cohort studies (compared to case-control studies), this was not 
strongly associated with study design. This heterogeneity could reflect wide variation in analgesia 
ever use between study populations; however, it could also reflect a validity problem with this unit 
of measurement—in which self-report (particularly retrospective) does not adequately capture the 
true prevalence of analgesia ever use. Also, we must accept that there are limitations in assuming 
that analgesia use reported by mothers is synonymous with actual intrauterine exposure by the 
foetus. 
While there were few studies that had investigated a possible dose-response relationship, we did 
observe a pattern of increasing risk of cryptorchidism with increasing number of weeks of analgesia 
exposure. However, as with ever use there is likely to be misclassification of the exposure. Ideally, 
we would measure dosage and frequency of use over the course of a woman's pregnancy; but in this 
case, the exposure was simply the number of weeks during which any given amount of analgesia 
was taken. 
Finally, we did observe a pattern of increased cryptorchidism risk when analgesia was consumed 
during the middle of pregnancy (largely coinciding with the second trimester) relative to early and 
late pregnancy (Jensen et al., 2010; Kristensen et al., 2011; Snijder et al., 2012). Both Jensen et al. 
(2010) and Phillippat et al. (2011) observed a somewhat higher risk of cryptorchidism among those 
exposed to analgesia during early- to mid-pregnancy than those exposed at any time during 
pregnancy, suggestive of a pathway by which analgesia may disrupt the first phase of testicular 
descent; however, the risk estimates (adjusted ORs: 1.14 and 1.20, respectively) and their associated 
CIs suggest that evidence of this scenario is weak. The issues relating to poor exposure 
measurement are also relevant here. 
It was our original intention to conduct separate stratified analyses for those boys diagnosed by 
clinical examination and those diagnosed via corrective orchidopexy, in an effort to understand 
whether the relationship between analgesia use and cryptorchidism differed according to disease 
severity and/or persistence. However, the vast majority (8 of 10) of the included studies used 
clinical diagnosis at birth (or shortly afterward). Thus, we were unable to examine this relationship 
in any meaningful way. 
Plausibility of analgesia as a cause of cryptorchidism 
The biological plausibility of analgesia exposure during pregnancy as a risk factor for 
cryptorchidism in the son rests on the premise that this exposure disturbs the normal endocrine 
processes responsible for testicular descent in utero. Similar versions of the mechanism by which 
this disruption is proposed to occur have been put forward in the literature: namely, that 
cyclooxygenase (COX)-inhibiting analgesia taken during the critical ‘male programming window’ 
(sometime between 8 and 15 weeks gestation) diminishes normal androgen activity (Kristensen et 
al., 2012), causing a potentially critical disruption to this first phase of testicular descent by 
interfering with prostaglandin synthesis (Jensen et al., 2010; Kristensen et al., 2011; Snijder et al., 
2012). 
However, biological plausibility and aetiological reality are not synonymous concepts. Firstly, as 
noted earlier evidence is unclear regarding the relationship between the timing of analgesia use and 
cryptorchidism development—somewhat contradicting the hypothesis that analgesia use during the 
‘male programming window’ and cryptorchidism development are strongly related. Secondly, there 
are similarly plausible arguments that suggest maternal analgesia use might cause other congenital 
anomalies—but there is little evidence that this is actually the case. For example, Rebordosa et al. 
(2008) compared 26 000 children who were exposed to acetaminophen during early pregnancy with 
62 000 children who were not, and found no increased risk of congenital abnormality, regardless of 
whether they were ever-exposed (adjusted HR: 1.01, 95% CI: 0.93–1.08) or exposed for more than 
4 weeks during pregnancy (adjusted HR, compared to never-exposed: 1.04. 95% CI: 0.89–1.21). 
The weak associations reported here must also be viewed in the context of other research which has 
found that low-dose aspirin may be protective against other health outcomes, including pre-
eclampsia (Henderson et al., 2014), as well as the ongoing debate regarding whether pre-conceptual 
aspirin use may (or may not) prevent pregnancy loss in high-risk populations (Schisterman et al., 
2014). 
The role of confounding 
Adjustment for confounding among those studies that presented both crude and adjusted risk 
estimates generally had little impact on the strength of the given association. For example, Jensen et 
al. (2010) reported near-identical crude and adjusted HRs despite adjusting for a number of 
potential confounders. The authors also conducted multiple sensitivity analyses with further 
potential confounders to their models, but again observed very little variation in terms of 
association strength (Jensen et al., 2011). This suggests that the relationship between analgesia use 
and risk of cryptorchidism is not noticeably affected by confounding. 
Limitations 
Our review has limitations. Firstly, like all systematic reviews the current manuscript is open to 
reporting bias, wherein those studies that observe the strongest effect are more likely to be 
published. Secondly, because of scant data, we were unable to conduct meta-analyses for two of our 
key study questions (relating to dose-response and timing of exposure). Thirdly, 9 of the 10 
included studies were conducted in either Europe or the US, limiting the generalizability of our 
observations to non-Western populations. 
Lastly, the current review grouped together medications based on their common effect—i.e. 
analgesia taken to alleviate pain. This grouping is largely in keeping with the idea that COX-
inhibiting analgesia diminishes normal androgen activity by interfering with prostaglandin 
synthesis; however, it is still possible that these medications may be heterogeneous with respect to 
both the means by, and extent to, which they may affect testicular descent. For example, Jensen et 
al.(2010) observed a moderate association between acetaminophen exposure and cryptorchidism, 
but little evidence of such an effect from ibuprofen and acetylsalicylic acid. It was our initial 
intention to stratify our analyses by medication group, but this was abandoned when it was 
discovered that many of the included manuscripts conflated these medications into an ‘any-use’ 
category (Table III). Thus, the current review offers little insight into the relationship between 
specific types of analgesia and cryptorchidism development. 
Conclusions 
We observed weak evidence of an association between ever use of analgesia and risk of 
cryptorchidism. Due to the likely mismeasurement of the exposure we cannot rule out the 
possibility that this measure underestimates the association between a non-trivial dose of analgesic 
during pregnancy and cryptorchidism. We observed weak evidence of a dose-response relationship 
between increasing weeks of analgesia exposure and risk of cryptorchidism, but finer-grained 
assessments (including measurement of actual dosage and frequency of use) are required to 
substantiate this relationship. We observed weak evidence of an association between the timing of 
analgesia exposure and risk of cryptorchidism, whereby those boys exposed during early- to mid-
pregnancy appeared to be marginally more at risk than those who were ever-exposed; however, risk 
estimates were close to the null and CIs were wide. This review highlights the need for further 
detailed assessments of the relationship between maternal analgesia use and risk of cryptorchidism. 
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